Lynparza (olaparib) has been approved in the European Union for the first-line maintenance treatment with bevacizumab of patients with homologous recombination deficient-positive advanced ovarian cancer.
Japan's Ministry of Health, Labor and Welfare has issued marketing authorization for Foundation for Biomedical Research and Innovation at Kobe to manufacture and supply commercial Kymriah (tisagenlecleucel) for patients in Japan.
Merck and VelosBio Inc. have entered into a definitive agreement, where Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75 billion in cash.
The next-generation sequencing-based FoundationOne CDx test has received FDA approval as a companion diagnostic to identify fusions in neurotrophic receptor tyrosine kinase genes, NTRK1, NTRK2, and NTRK3, in DNA isolated from tumor tissue specimens from patients with solid tumors eligible for treatment with Vitrakvi (larotrectinib).
FDA has approved expanded claims for the cobas EGFR Mutation Test v2 as a companion diagnostic for a broad group of therapies in the treatment of non-small cell lung cancer.
CPI-613 (devimistat) received Orphan Drug designation from FDA for the treatment of soft tissue sarcoma.
Exact Sciences Corp. and Thrive Earlier Detection Corp. have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion.
EQRx has licensed two late-stage immuno-oncology agents from CStone Pharmaceuticals. The licensing agreement covers sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1).
The StrataNGS test has received coverage under Medicare by Palmetto GBA, a Medicare Administrative Contractor, for patients with advanced stages (III or IV), recurrent, relapsed, refractory, and/or metastatic solid tumors.
FDA has approved FoundationOne Liquid CDx for three new companion diagnostic indications to help match patients who may benefit from treatment with specific FDA-approved targeted therapies.
